发明名称 BENZENE RING-FUSED, NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLIC COMPOUND OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
摘要 <p>[Problem] To provide a novel compound having EP1 receptor antagonist activity, or a pharmacologically acceptable salt thereof. [Solution] A benzene ring-fused, nitrogen-containing 5-membered heterocyclic compound indicated by general formula (I) or a pharmacologically acceptable salt thereof was found to have powerful EP1 receptor antagonist activity. The compound (I) or a pharmacologically acceptable salt thereof is effective as a therapeutic medication or preventative medication for lower urinary tract symptoms (LUTS), for example, and overactive bladder syndrome (OABs), etc., in particular. In addition, the compound (I) or a pharmacologically acceptable salt thereof is highly useful in the treatment, prevention, or suppression of a variety of conditions involving EP1 receptors, in addition to lower urinary tract symptoms (LUTS) (e.g., inflammatory conditions, painful conditions, osteoporosis, cancer, etc.).</p>
申请公布号 WO2014017093(A1) 申请公布日期 2014.01.30
申请号 WO2013JP04520 申请日期 2013.07.24
申请人 KYORIN PHARMACEUTICAL CO., LTD.;KISSEI PHARMACEUTICAL CO., LTD. 发明人 SETO, SHIGEKI;UMEI, KENTARO;TANIOKA, ASAO;TATANI, KAZUYA
分类号 C07D413/06;A61K31/423;A61K31/428;A61K31/4355;A61K31/4439;A61K31/454;A61K31/497;A61K31/5377;A61K31/541;A61K31/55;A61P13/02;A61P13/10;A61P43/00;C07D417/04;C07D417/06;C07D417/14;C07D491/113;C12N15/09 主分类号 C07D413/06
代理机构 代理人
主权项
地址